Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : IMS001
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Recipient : AgeX Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : ImStem has obtained from AgeX a non-exclusive, royalty-bearing sublicense to use AgeX’s clinical-grade ESC line ESI-053 to derive ImStem’s investigational MSC product candidate IMS001 for development in COVID-19 as well as acute respiratory distress ...
Brand Name : IMS001
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 28, 2020
Lead Product(s) : IMS001
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Recipient : AgeX Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : IMS001
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : AgeX Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : ImStem will obtain from AgeX a non-exclusive license to use AgeX’s embryonic stem cell line ESI 053 to derive ImStem’s investigational MSC product IMS001 for development in COVID-19 as well as acute respiratory distress syndrome due to other causes.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 02, 2020
Lead Product(s) : IMS001
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : AgeX Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?